ADC Therapeutics
Innovating Science. Inspiring Hope.
Innovating Science. Inspiring Hope.
ADC Therapeutics is a commercial-stage biotechnology company focused on improving the lives of cancer patients through the development of targeted antibody drug conjugates (ADCs). With the recent FDA approval of ZYNLONTA®, the company's ADC platform has been validated, showcasing its potential to address significant unmet medical needs in the oncology treatment landscape. Founded in 2011, ADC Therapeutics is headquartered in Lausanne, Switzerland, with operations in London, New Jersey, and the San Francisco Bay Area. The company's latest post-IPO equity investment of $60.00M in February 2023 highlights its continuing growth and potential in the biopharma and biotechnology industries. ADC Therapeutics' commitment to leveraging its science to bring hope and unique therapies to cancer patients is evidenced by its global team's dedication to this cause. For more information, please visit ADC Therapeutics and follow the company on Twitter @adctherapeutics.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $105.00M | - | 06 May 2024 | |
| Post-IPO Equity | $60.00M | - | 02 Feb 2023 | |
| Post-IPO Debt | $50.00M | 1 | Deerfield | 17 May 2021 |
| Post-IPO Debt | $65.00M | 1 | Deerfield | 15 May 2020 |
| Series E | Fr.25.00M | - | 09 Jul 2019 |
No recent news or press coverage available for ADC Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
